Published date: Mar 10 2024

Journal Title: Journal of Ophthalmic and Vision Research

Issue title: Jan–Mar 2024, Volume 19, Issue 1

Pages: 1–3

DOI: 10.18502/jovr.v19i1.15415

Hadi MohammadiDepartment of Medical Physics and Biomedical Engineering, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Hashem Rafii-Tabarrafii-tabar@nano.ipm.ac.irDepartment of Medical Physics and Biomedical Engineering, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

This is an Editorial and does not have an abstract. Please download the PDF or view the article in HTML.

Keywords: N/A

1. Wang AL, Knight DK, Thanh-thao TV, Mehta MCJIoc. Retinitis pigmentosa: Review of current treatment. Int Opthalmol Clin 2019;59:263–280.

2. García-Layana A, Cabrera-López F, García-Arumí J, Arias- Barquet L, Ruiz-Moreno JMJCiia. Early and intermediate age-related macular degeneration: Update and clinical review. Clin Interv Aging 2017;12:1579–1587.

3. Pennington KL, DeAngelis MM. Epidemiology of agerelated macular degeneration (AMD): Associations with cardiovascular disease phenotypes and lipid factors. Eye Vis 2016:3:34.

4. Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RPJBJoO. Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis. Br J Ophthalmol 2020;104:1077–1084.

5. Mata NL, Vogel RJCoio. Pharmacologic treatment of atrophic age-related macular degeneration. Curr Opin Ophthalmol 2010;21:190–196.

6. Schmidt-Erfurth U, Hasan TJSoo. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195–214.

7. Holz FG, Schmitz-Valckenberg S, Fleckenstein MJTJoci. Recent developments in the treatment of age-related macular degeneration. J Clin Invest 2014;124:1430–1438.

8. da Cruz L, Dorn JD, Humayun MS, Dagnelie G, Handa J, Barale P-O, et al. Five-year safety and performance results from the Argus II retinal prosthesis system clinical trial. Ophthalmology 2016;123:2248–2254.

9. Stingl K, Bartz-Schmidt KU, Besch D, Chee CK, Cottriall CL, Gekeler F, et al. Subretinal visual implant alpha IMS – Clinical trial interim report. Vision Res 2015;111:149–160.

10. Winter JO, Cogan SF, Rizzo J. Retinal prostheses: Current challenges and future outlook. J Biomater Sci Polym Ed 2007;18:1031–1055.

11. Picaud S, Sahel J-A. Retinal prostheses: Clinical results and future challenges. C R Biol 2014;337:214–222.

12. Schmid EW, Fink W, Wilke R. Operational challenges of retinal prostheses. Med Eng Phys 2014;36:1644–1655.

13. Zeng Q, Huang Z. Challenges and opportunities of implantable neural interfaces: From material, electrochemical and biological perspectives. Adv Funct Mater 2023;33:2301223.

14. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine for the treatment of retinal and optic nerve diseases. Curr Opin Pharmacol 2013;13:134–148.

15. Zarbin MA, Arlow T, Ritch R. Regenerative nanomedicine for vision restoration. Mayo Clin Proc 2013;88:1480–1490.

16. Gómez-Garzón M, Martínez-Ceballos MA, Gómez-López A, Rojas-Villarraga A. Application of nanotechnology in ophthalmology: Where are we? Charact Appl Nanomater 2022;5:66–78.

17. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine in ophthalmology: The new frontier. Am J Ophthalmol 2010;150:144–162.e2.

18. Tang Z, Fan X, Chen Y, Gu P. Ocular nanomedicine. Adv Sci 2022;9:e2003699.

19. Herrera-Barrera M, Ryals RC, Gautam M, Jozic A, Landry M, Korzun T, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv 2023;9:eadd4623.

20. Chien Y, Hsiao Y-J, Chou S-J, Lin T-Y, Yarmishyn AA, Lai W-Y, et al. Nanoparticles-mediated CRISPRCas9 gene therapy in inherited retinal diseases: Applications, challenges, and emerging opportunities. J Nanobiotechnology 2022;20:511.

21. Tawfik M, Chen F, Goldberg JL, Sabel BA, et al. Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy. Naunyn Schmiedebergs Arch Pharmacol 2022;395:1477–1507.

22. Eleftheriou CG, Zimmermann JB, Kjeldsen HD, David-Pur M, Hanein Y, Sernagor E. Carbon nanotube electrodes for retinal implants: A study of structural and functional integration over time. Biomaterials 2017;112:108–121.

23. Bareket L, Waiskopf N, Rand D, Lubin G, David-Pur M, Ben- Dov J, et al. Semiconductor nanorod–carbon nanotube biomimetic films for wire-free photostimulation of blind retinas. Nano Lett 2014;14:6685–6692.

24. Riva ER, Micera S. Section 4–Nanotechnology-based neuronal interfaces. p. 16.

25. Zhao D, Huang R, Gan J-M, Shen Q-D. Photoactive nanomaterials for wireless neural biomimetics, stimulation, and regeneration. ACS Nano 2022;16:19892–19912.

26. Choi C, Choi MK, Liu S, Kim M, Park OK, Im C, et al. Human eye-inspired soft optoelectronic device using high-density MoS2-graphene curved image sensor array. Nat Comm 2017;8:1664.

27. Ghaffari M, Moztarzadeh S, Rahmanian F, Yazdanpanah A, Ramedani A, Mills DK, et al. Nanobiomaterials for bionic eye: Vision of the future. Eng Nanobiomater 2016;2:257– 285.

28. Tang J, Qin N, Chong Y, Diao Y, Yiliguma, Wang Z, et al. Nanowire arrays restore vision in blind mice. Nat Commun 2018;9:786.

29. Jackson TL, Mandava N, Quiroz-Mercado H, Benage M, Garcia-Aguirre G, Morales-Canton V, et al. Intravitreal quantum dots for retinitis pigmentosa: A first-in-human safety study. Nanomedicine 2021;16:617–626.

30. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969–976.

31. Olson JL, Velez-Montoya R, Mandava N, Stoldt CR. Intravitreal silicon-based quantum dots as neuroprotective factors in a model of retinal photoreceptor degeneration. Invest Ophthalmol Vis Sci 2012;53:5713–5721.

32. Olson J, Velez-Montoya R, Mandava N, Stoldt CR. Neuroprotective effect of photoactive quantum dots in progressive retinal photoreceptor degeneration. J Nanomater Mol Nanotechnol 2013;7:2.